Claims for Patent: 11,986,554

Summary for Patent: 11,986,554

Title:	Orally disintegrating compositions
Abstract:	An orally disintegrating dosage form of a proton pump inhibitor, methods for its production and use thereof are provided. The dosage form includes a plurality of pellets containing a proton pump inhibitor admixed with a disintegrant to afford rapid disintegration in the oral cavity after administration.
Inventor(s):	Sheera Moses-Heller
Assignee:	Dexcel Pharma Technologies Ltd
Application Number:	US17/389,612
Patent Claims:	1. An orally disintegrating tablet comprising (i) enteric coated active cores comprising about 2 mg to about 50 mg of a proton pump inhibitor selected from the group consisting of lansoprazole, omeprazole, pantoprazole, leminoprazole, perprazole, rabeprazole, and a pharmaceutically acceptable salt thereof; and (ii) at least one pharmaceutically acceptable excipient comprising a disintegrant comprising cross-linked polyvinylpyrrolidone, the enteric coated active cores comprising: (a) inert seeds comprising sugar spheres; (b) a drug coating layer over the inert seeds, wherein the drug coating layer comprises the proton pump inhibitor and mannitol, wherein the drug coating layer further comprises at least one alkalizing agent selected from the group consisting of arginine, lysine, meglumine, a stearic acid salt, sodium hydroxide, potassium hydroxide, calcium carbonate, magnesium carbonate, and zinc carbonate, in an amount of about 1% to about 5% by weight of the total composition; (c) a subcoating layer over the drug coating layer, wherein the subcoating layer comprises hydroxypropyl methylcellulose; and (d) a single enteric coating layer in an amount of about 10% to about 25% by weight of the total composition over the subcoating layer, wherein the enteric coating layer comprises hydroxypropyl methylcellulose phthalate and cetyl alcohol, wherein the enteric coated active cores together with the at least one pharmaceutically acceptable excipient comprising a disintegrant are compressed into the form of a tablet, wherein the tablet substantially disintegrates in the oral cavity of a subject in need thereof within less than about 60 seconds after administration and provides a delayed release profile of the proton pump inhibitor, and wherein in vitro drug release in 15 minutes at 0.1N HCl and 40% ethanol is less than about 20%. 2. The orally disintegrating tablet of claim 1, wherein the amount of the inert seeds is in the range of from about 2% to about 10% by weight of the total composition. 3. The orally disintegrating tablet of claim 1, wherein the amount of the proton pump inhibitor is in the range of from about 3% to about 9% by weight of the total composition. 4. The orally disintegrating tablet of claim 1, wherein the amount of the subcoating layer is in the range of from about 5% to about 15% by weight of the total composition. 5. The orally disintegrating tablet of claim 1, wherein the proton pump inhibitor comprises 15 mg or 30 mg lansoprazole. 6. The orally disintegrating tablet of claim 1, wherein the amount of the disintegrant is in the range of from about 2% to about 15% by weight of the total composition. 7. The orally disintegrating tablet of claim 1, wherein the proton pump inhibitor comprises lansoprazole. 8. The orally disintegrating tablet of claim 1, wherein the pharmaceutically acceptable excipient further comprises at least one of a binder, a filler, an anti-tacking agent, a lubricant, a glidant, a surfactant, a plasticizer or a combination thereof in an amount of not more than about 30% by weight of the total composition. 9. The orally disintegrating tablet of claim 1, wherein the at least one alkalizing agent comprises meglumine. 10. The orally disintegrating tablet of claim 1, having a hardness of at least 20 Newtons. 11. The orally disintegrating tablet of claim 1, wherein in vitro drug release in 15 minutes at 0.1N HCl and 40% ethanol is less than about 20% after storage for 7 months at 25° C. and 60% Relative Humidity. 12. The orally disintegrating tablet of claim 1, wherein the enteric coating layer over the subcoating layer further comprises triethyl citrate. 13. The orally disintegrating tablet of claim 1, comprising meglumine and lansoprazole in the drug coating layer.